English
Back
Open Account
2026 IPO bonanza! Over 90% of new stocks rose on their debut!
牛牛新股君
joined discussion · Mar 30 07:37

IPO Pricing | Dishi-B debuts today with over 1,000 times subscription, priced at HKD 99 per share, earning over HKD 5,000 per lot in the grey market

Futu Information reported on March 30 $DIAGENS-B (02526.HK)$ Announced the allotment results, priced at HKD 99 per share, issuing a total of 7,999,200 shares, with each lot consisting of 50 shares, and officially listed today
In the last trading session, Deshi-B's dark pool closed up 101.52% at HKD 199.5. Each lot consists of 50 shares, and without considering handling fees, a profit of HKD 5,025 was made per lot.
During the public offering phase, Deshi-B received 1,073.37 times subscription. The final number of shares offered to the public was 799,950 shares, accounting for approximately 10% of the total shares issued. A total of about 115,017 valid applications were received, with approximately 14,278 accepted applications. The approximate percentage of shares allocated to one-lot subscribers out of the total applied shares was 3%.
In addition, during the international placement phase, Deshi-B received 3.45 times subscription. The final number of international placement shares was 71,992,500 shares, equivalent to 90% of the total shares issued. Futu Information has compiled the relevant data in the following table:
Futu Information reported on March 30 $DIAGENS-B (02526.HK)$ Announced the allotment results, priced at HKD 99 per share, issuing a total of 7,999,200 shares, with each lot consisting of 50 shares, and officially listed today On the last trading day, Dishi-B's grey market closed up 101.52% at HKD 199.50, with each lot consisting of 50 shares, earning HKD 5,025 per lot excluding fees During the public offering stage, Dishi-B received 1,073.37 times subscription, with the final number of shares offered to the public amounting to 799,950 shares, representing approximately 10% of the total shares offered. A total of around 115,017 valid applications were received, with about 14,278 accepted applications, and the approximate percentage of allotted shares for one-lot subscribers compared to the total applied shares was 3% In addition, during the international placement stage, Dishi-B received 3.45 times subscription, with the final number of international placement shares amounting to 7,199,250 shares, equivalent to 90% of the total shares offered. Futu Information compiled the relevant data in the table below Company Overview Dishi is a medical device company focused on developing medical imaging products and services, having developed a diversified product portfolio including six medical imaging software products (one core product in registration stage AI AutoVision®, one commercialized product AutoVision®, four other pre-clinical stage medical imaging software candidates), three commercialized medical devices...
Futu Information reported on March 30 $DIAGENS-B (02526.HK)$ Announced the allotment results, priced at HKD 99 per share, issuing a total of 7,999,200 shares, with each lot consisting of 50 shares, and officially listed today On the last trading day, Dishi-B's grey market closed up 101.52% at HKD 199.50, with each lot consisting of 50 shares, earning HKD 5,025 per lot excluding fees During the public offering stage, Dishi-B received 1,073.37 times subscription, with the final number of shares offered to the public amounting to 799,950 shares, representing approximately 10% of the total shares offered. A total of around 115,017 valid applications were received, with about 14,278 accepted applications, and the approximate percentage of allotted shares for one-lot subscribers compared to the total applied shares was 3% In addition, during the international placement stage, Dishi-B received 3.45 times subscription, with the final number of international placement shares amounting to 7,199,250 shares, equivalent to 90% of the total shares offered. Futu Information compiled the relevant data in the table below Company Overview Dishi is a medical device company focused on developing medical imaging products and services, having developed a diversified product portfolio including six medical imaging software products (one core product in registration stage AI AutoVision®, one commercialized product AutoVision®, four other pre-clinical stage medical imaging software candidates), three commercialized medical devices...
Company Overview
Dexi is a medical device company specializing in the development of medical imaging products and services. It has developed a diversified portfolio of products, including six medical imaging software products (one core product at the registration stage: AI AutoVision®, one commercialized product: AutoVision®, and four other pre-clinical medical imaging software candidates), three commercialized medical devices, four key reagents and consumables, and two technology-licensed products.
According to Frost & Sullivan, based on 2024 revenue, the company ranks first in China’s chromosome karyotype analysis sector with a market share of 30.6%. The company's leading position is built upon its excellent track record in research and development as well as commercialization, including the success of its proprietary computer-aided chromosome analysis software, AutoVision®.
The core technological advantage of the key product AI AutoVision® lies in the company’s self-developed iMedImage® medical imaging foundational model. As of the latest practicable date, it can effectively support 19 types of medical imaging modalities (such as chromosomes, CT, MRI, ultrasound, and pathology) and cover more than 90% of clinical medical imaging scenarios, including reproductive health, hematological malignancies, and other clinical applications.
Financial Overview
Dexi's revenue increased by 33.1% from RMB 52.8 million in 2023 to RMB 70.4 million in 2024, primarily due to income generated from technology licensing in 2024. In 2023 and 2024, as well as for the nine months ended September 30, 2024, and 2025, the company’s gross profits were RMB 37.5 million, RMB 46.1 million, RMB 8.4 million, and RMB 84.7 million, respectively. During the same periods, the company’s gross profit margins were 71.0%, 65.5%, 42.9%, and 75.9%, respectively.
Futu Information reported on March 30 $DIAGENS-B (02526.HK)$ Announced the allotment results, priced at HKD 99 per share, issuing a total of 7,999,200 shares, with each lot consisting of 50 shares, and officially listed today On the last trading day, Dishi-B's grey market closed up 101.52% at HKD 199.50, with each lot consisting of 50 shares, earning HKD 5,025 per lot excluding fees During the public offering stage, Dishi-B received 1,073.37 times subscription, with the final number of shares offered to the public amounting to 799,950 shares, representing approximately 10% of the total shares offered. A total of around 115,017 valid applications were received, with about 14,278 accepted applications, and the approximate percentage of allotted shares for one-lot subscribers compared to the total applied shares was 3% In addition, during the international placement stage, Dishi-B received 3.45 times subscription, with the final number of international placement shares amounting to 7,199,250 shares, equivalent to 90% of the total shares offered. Futu Information compiled the relevant data in the table below Company Overview Dishi is a medical device company focused on developing medical imaging products and services, having developed a diversified product portfolio including six medical imaging software products (one core product in registration stage AI AutoVision®, one commercialized product AutoVision®, four other pre-clinical stage medical imaging software candidates), three commercialized medical devices...
Source: Prospectus
Source: Prospectus
Use of Proceeds
Regarding the use of proceeds, Deshi is expected to receive net proceeds from the global offering of approximately HKD 719.8 million (based on an offer price of HKD 99). According to the prospectus, Deshi intends to allocate the proceeds from the global offering for the following purposes in the specified amounts:
Approximately 49% will be allocated to the research and development and commercialization of the company's core product, AI AutoVision®; about 10% will be allocated within three years post-listing to further the development of the company’s other medical imaging software candidates and medical devices; around 20% will be used to strengthen the company’s iMedImage® foundational model and AI technologies; about 8% will be allocated to enhance the company’s commercial capabilities and market penetration in China; roughly 5% will be used to expand the company’s business in global markets by hiring approximately two junior local sales representatives, eight mid-level local sales representatives, and nine senior local sales representatives; and about 8% will be allocated to seeking strategic cooperation and investment opportunities with upstream and downstream participants in the healthcare value chain.
The golden season for new stock subscriptions has arrived! Use Futu for new stock subscriptions—zero interest, zero handling fees, and zero cash subscription. Participants now have the chance to have their new stock subscription fees waived for a year.Come and experience it now >>
Futu Information reported on March 30 $DIAGENS-B (02526.HK)$ Announced the allotment results, priced at HKD 99 per share, issuing a total of 7,999,200 shares, with each lot consisting of 50 shares, and officially listed today On the last trading day, Dishi-B's grey market closed up 101.52% at HKD 199.50, with each lot consisting of 50 shares, earning HKD 5,025 per lot excluding fees During the public offering stage, Dishi-B received 1,073.37 times subscription, with the final number of shares offered to the public amounting to 799,950 shares, representing approximately 10% of the total shares offered. A total of around 115,017 valid applications were received, with about 14,278 accepted applications, and the approximate percentage of allotted shares for one-lot subscribers compared to the total applied shares was 3% In addition, during the international placement stage, Dishi-B received 3.45 times subscription, with the final number of international placement shares amounting to 7,199,250 shares, equivalent to 90% of the total shares offered. Futu Information compiled the relevant data in the table below Company Overview Dishi is a medical device company focused on developing medical imaging products and services, having developed a diversified product portfolio including six medical imaging software products (one core product in registration stage AI AutoVision®, one commercialized product AutoVision®, four other pre-clinical stage medical imaging software candidates), three commercialized medical devices...
Editor/Joe
Risk Disclaimer: The above content only represents the author's view. It does not represent any position or investment advice of Futu. Futu makes no representation or warranty.Read more
Thumbs Up
9
Respect
1
137K Views
Report
Comments
Write a Comment...
10
24